6% of cerebral palsy after hypoxic-ischemic encephalopathy. Inflammatory markers occurred in 13.9% and 11.9% of these outcomes, respectively. Growth restriction contributed significantly to all poor outcome groups. Birth defects were recognized in 5.5% of neonates in the control group compared with 60% of neonatal deaths and more than half of cases of cerebral palsy without hypoxic-ischemic encephalopathy. In children with cerebral palsy, a potentially asphyxial birth event, inflammation, or both were experienced by 12.6%, whereas

growth restriction, a birth defect, or both were experienced by 48.6% (P<.001).

CONCLUSION: Fetal growth restriction and birth defects recognized by age 6 years were more substantial contributors Selleckchem Ruboxistaurin NSC23766 concentration to cerebral palsy and neonatal death than potentially asphyxial birth events and inflammation.”
“Objective: The present paper reports about the content and evaluation of a psycho-educational group intervention for children growing up with a history of cancer, Op Koers Oncologie (OK Onco). OK Onco is aimed at empowerment of survivors of childhood cancer by teaching disease-related skills. The purpose of this pilot study is to evaluate whether OK Onco was appropriate for use among paediatric survivors of childhood cancer.

Methods: Eleven participating children and their parents completed questionnaires about the disease-related skills that were taught in the

intervention, before the intervention and 0-4 weeks after the intervention. In addition, parents were interviewed in focus groups.

Results: Positive outcomes were found on most items concerning disease-related this website skills. Remarkable improvements were found with respect to the intervention goals ‘social competence’ and ‘positive thinking’.

The parents reported that sharing emotions and experiences with other survivors of childhood cancer was an important element of the OK Onco program, which underscores the benefit of a disease-specific program for cancer survivors.

Conclusions: In conclusion, the results of the pilot study indicate that OK Onco is appropriate for paediatric survivors of childhood cancer. Implementation of the intervention is the next challenge. Copyright (C) 2008 John Wiley & Sons, Ltd.”
“Studies of our laboratory have led to elaboration of the DEAMOX (DEnitrifying AMmonia OXidation) technology intended for removal of nitrogen contaminants from wastewater. The DEAMOX process comprises two anaerobic stages implemented by the same sludge biocatalyst, namely, denitratation (conversion of nitrate to nitrite) and anammox reaction (ANaerobic AMmonium nitrogen OXidation by nitrite). The results of reactivation of biocatalysts after their long-term storage (5 and 16 months) and successful startup of the DEAMOX process in two modifications (S- and O-) are described. An S-DEAMOX process was launched using a sludge biocatalyst with restored anammox activity of 20.